Your browser is outdated! Try to open this webpage in another browser.
Aller au contenu

ArchiMed

ArchiMed

ArchiMed is an independent Lyon-based investment firm founded in 2014 and acts as a strategic financial partner for European healthcare companies.

As at December 31, 2022

ArchiMed launched MED Platform I in 2018 and MED Platform II in 2022. These vehicles aim to accelerate the growth of European and American companies selected primarily because of their potential to expand internationally and take part in sector consolidation.

By the end of 2022, MED Platform I had raised €1 billion and had invested in seven platforms and sold one of its investments: Bomi Group (a leading European provider of specialist contract logistics for medical equipment manufacturers: investment made in 2019 and sold in 2022 for a return of 3.8x), Direct Healthcare Group (a leading European provider of specialist hospital equipment for the prevention and treatment of pressure ulcers, investment made in late 2019), NAMSA (a world-leading contract research provider to medical equipment manufacturers, investment made in 2020), Stragen (a pharmaceuticals company specialising in complex generic drugs in niche markets, investment made in 2021), Prollenium (producer of medical aesthetic products specialising in cutaneous injections of hyaluronic acid, investment made in 2021), Suanfarma (producer and distributor of pharmaceutical and nutraceutical products, investment made in 2021) and Carso (joint leader in the French testing services market, investment made in 2021).

At the end of 2022, the seven platforms had carried out a total of 34 add-on acquisitions, including 15 for Bomi and 6 for DHG.

Investment date
2018

Team

MED Platform I is managed by four partners: Denis Ribon, a well-known investor in the healthcare sector and co-founder of ArchiMed in 2014, Antoine Faguer, investor and entrepreneur, and Benoît Adelus and André-Michel Ballester, who have both successfully managed and developed several mid-cap healthcare companies.

Peugeot Invest's investment

In 2018, Peugeot Invest committed to invest up to €80 million, with the potential to double its exposure to companies of its choosing, taking its maximum commitment to €160 million. In 2022, Peugeot Invest made a commitment of €100 million to MED Platform II.

In 2021, Peugeot Invest committed to co-invest a further €32 million across three of the fund’s platforms (Carso, Prollenium and Suanfarma). In 2022, an additional commitment of $10 million was made in relation to Natus.

In 2022

In 2022, the MED Platform II fund had raised over €2.5 billion and made its first two investments: Natus Medical (US company specialising in diagnostic equipment and treatments for disorders affecting the central nervous system and sensory system) and Plasmidfactory (Germany producer of plasmid DNA, which is used in making messenger RNA vaccines and in gene and cell therapies).